EntryPoint Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

EntryPoint Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,951	Closed	-$377K	–	863
2025 Q2	$377K	Sell	11,951 -461	-4%	-$14.8K	0.19%	188
2025 Q1	$406K	Buy	+12,412	New	+$440K	0.19%	183
2024 Q2	–	Sell	-1,274	Closed	-$43.5K	–	1587
2024 Q1	$43.5K	Buy	+1,274	New	+$37.9K	0.04%	827

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EntryPoint Capital's SUPN Position: Q3 2025 in Review

EntryPoint Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 11,951 shares — an estimated $377K sold.

EntryPoint Capital first reported a position in SUPN in Q1 2024 and held it in 3 quarters. The position peaked at $406K in Q1 2025. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

EntryPoint Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 11,951 Supernus Pharmaceuticals shares in Q3 2025, an estimated $377K.
EntryPoint Capital first reported a position in Supernus Pharmaceuticals in Q1 2024 and held it in 3 quarters.
EntryPoint Capital's Supernus Pharmaceuticals position peaked at $406K in Q1 2025.
310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.